Table 1. Time from estimated date of infection (EDI) to ART initiation and CD4/CD8 cell ratios, CD4, and CD8 counts at baseline and week 24–48 follow up visits after initiating ART.
| Characteristics and Time points | Number of individuals | Time from EDI to ART initiation (days, range) | Baseline CD4/CD8 cell ratio (median, range) | Week 24-48 CD4/CD8 cell ratio (median, range) | p-value (Wilcoxons signed rank test) | Baseline CD4 cell count, cells/mm3 (median, range) | Week 24-48 CD4 cell count, cells/mm3 (median, range) | p-value (Wilcoxons signed rank test) | Baseline CD8 cell count, cells/mm3 (median, range) | Week 24–48 CD8 cell count, cells/mm3 (median, range) | p-value (Wilcoxons signed rank test) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute HIV infection | 36 (42%) | 25 (10–40) | 0.59 (0.07–2.60) | 1.15 (0.48–3.97; n = 29) | <0.001 | 456 (67–1113) | 827 (283–1539; n = 29) | <0.001 | 744 (110–6055) | 791 (338–1476; n = 29) | n.s. |
| Early HIV infection | 27 (31%) | 91 (36–194) | 0.65 (0.06–1.45) | 1.02 (0.42–1.79; n = 24) | 0.001 | 590 (166–973) | 743 (434–1219; n = 24) | 0.002 | 830 (299–8777) | 843 (299–1264; n = 24) | n.s. |
| Chronic HIV infection | 23 (27%) | — | 0.42 (0.17–1.26) | 0.81 (0.28–2.04; n = 22) | <0.001 | 377 (111–958) | 597 (255–1523; n = 22) | <0.001 | 681 (378–2363) | 759 (298–1508; n = 22) | n.s. |